ArticleOncotarget2016

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.

Joel G Turner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.